Navigation Links
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Date:12/8/2012

ATRA+idarubicin (AIDA) treatment regimen. The primary study objective was event-free survival (EFS) at two years, with secondary objectives including overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR) rates, molecular response, and safety.

Results suggest that the targeted ATO+ATRA therapy strategy might offer similar efficacy to the chemotherapy-based regimen. In the 154 patients who were evaluable for response, complete remission was achieved in all patients (100%) in the ATO+ATRA arm and 95 percent in the AIDA arm. EFS was observed in 97 percent in the ATO+ATRA arm, with one death and two relapses, compared to 86.7 percent in the AIDA arm, in which seven deaths and four relapses were observed. Overall survival, DFS, and CIR rates were 98.7 percent, 97 percent, and 1.6 percent, respectively, in the ATO+ATRA arm, versus 91.1 percent, 91.6 percent, and 4.3 percent, respectively, in the AIDA arm. Additionally, fewer side effects (fever, low neutrophil and platelet counts) were observed in the ATO+ATRA arm.

"This is one of the first times that we can report the success of a treatment strategy for an acute leukemia that relies solely on targeted molecular therapy," said Francesco Lo-Coco, MD, lead author and Chairman of the APL subcommittee of the Italian GIMEMA group and Professor of Hematology at University Tor Vergata in Rome, Italy. "Our results are an important step toward the further utilization of targeted therapies for other types of leukemia, as we begin to focus on improving the overall treatment experience for patients by offering new strategies that deliver the same efficacy as traditional options with considerably lower toxicity."

Dr. Lo-Coco will present this study during the Plenary Scientific Session on Sunday, December 9, at 3:45 p.m. EST at the Georgia World Congress Center in Hall B5, Level 1, Building B.


'/>"/>
Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
2. Benefit6 Whole Body Protection, a New Product by I Do Strive LLC, Provides Increased Energy Production According to Recent Studies
3. Sharp spike in computer-related injuries predicted for medical workers, find studies
4. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
5. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
6. New studies show effects of mammography guideline changes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
9. Cancer Drug Reduced Relapses in MS Patients: Studies
10. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
11. Studies Show Limits, Promise of Laser Removal of Tattoos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Tenn. (PRWEB) , ... July 01, 2015 , ... The ... held rain or shine Saturday, July 11, 2015, at 6 p.m. in Pugh Bourne ... free and includes pony rides, a petting zoo, an Elvis impersonator, a silent auction ...
(Date:7/1/2015)... Miami, Florida (PRWEB) , ... July 01, 2015 ... ... effects for society,” said lead author Lisa Stolzenberg, a Professor in FIU’s School ... on juveniles aged 12 to 17 years who participated in the National Survey ...
(Date:7/1/2015)... ... July 01, 2015 , ... Element Blue ™, ... today that it has received trademark protection for its SensorInsight® computer software platform. ... data from multiple sources providing an environment where users can view and compare ...
(Date:7/1/2015)... San Luis Obispo, CA (PRWEB) , ... July ... ... in non-surgical bunion treatment, announces their big summer sale. Customers purchasing two ... $15 with promo code "Summer15". , Bunion Bootie temporarily corrects misaligned ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... healthcare providers, has been retained to lead a national chief executive officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
Breaking Medicine News(10 mins):Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3
... the birth,of a daughter to 17-year-old actress Jamie Lynn ... issued the following,statement from CEO Sarah Brown:, "Every ... Jamie Lynn,Spears, new daughter, Maddie Briann, will be surrounded ... that is sure to now erupt, as it,did when ...
... Federal Reserve chairman Ben Bernanke,s,comments this week that ... one of the biggest challenges facing the nation, plus ... rise nearly 10 percent this,year, lend strong support to ... wellness, according to U.S. Preventive Medicine, the leader,in disease ...
... Cohera Medical Inc. today announced,that data published in ... the company,s surgical adhesive, TissuGlu, was effective in ... model., Summarized in a paper titled "Lysine-Derived ... Abdominoplasty Model," (Plast.,Reconstr. Surg. 2008; Vol. 122, Issue ...
... working to develop inexpensive paper that can destroy, deactivate ... will share their expertise with the world as the ... next week in Espoo, Finland. More than 80 science, ... will meet in the city northwest of Helsinki for ...
... proposes $2.29 billion hospice rate,cut, WASHINGTON, ... providers representing all 50 states are calling ... the Administration from slashing,the hospice reimbursement under ... millions of Americans nearing the end of,their ...
... The plant, Kalanchoe fedtschenkoi, is unique because, unlike normal plants, ... the air is cooler and more humid, making it 10 ... Scientists will use the latest next-generation DNA sequencing to analyse ... at night. , The project will generate a genome ...
Cached Medicine News:Health News:National Campaign to Prevent Teen and Unplanned Pregnancy Statement on Jamie Lynn Spears 2Health News:U.S. Preventive Medicine Views Bernanke's Comments as Strong Support for Prevention and Wellness Programs 2Health News:Data Published in Plastic and Reconstructive Surgery Show Cohera Medical's Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model 2Health News:Data Published in Plastic and Reconstructive Surgery Show Cohera Medical's Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model 3Health News:World research leaders gather in Finland to accelerate the development of bioactive paper 2Health News:Hospice Programs Nationwide Urge Congress to Act on Behalf of End-of Life Patients 2
(Date:7/1/2015)... 2015 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... inflammatory disease and neurologic disorders, announced today the results ... citrate, the Company,s lead compound. Results from the study ... can significantly inhibit the activation of inflammatory proteins in ... this compound in a Phase 1 clinical trial under ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
(Date:6/30/2015)... Scotland , July 1, 2015 ... joins Nu C ana team   ... ProTide technology to develop and commercialise a portfolio of ... Chris McGuigan as Chief Scientific Officer. ... ProTide technology. He is currently Professor of Medicinal Chemistry ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3
... Amgen (Nasdaq: AMGN ), today announced the ... privately held biotechnology company based in Woburn, Mass., with ... a novel investigational oncolytic vaccine in Phase 3 clinical ... melanoma and head and neck cancer. The acquisition was ...
... , a leader in bioinformatics software and knowledge integration, ... license for Pathway Studio ® Enterprise system that ... MedScan® text processing technology for site-wide use. Pathway Studio ... pathways and develop mechanistic rationale for disease based on ...
Cached Medicine Technology:Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4Site-wide License for Ariadne's Pathway Studio Renewed by NCI 2
... OmniMD Medical Billing system allows a ... accounting. It is integrated with the ... The system interfaces with electronic clearinghouses ... With a set of reports, it ...
... CPNG3 single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... CPNG3 reagent provides a long shelf ...
... Infinity Uric Acid single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Uric Acid reagent provides a ...
... Oxidase single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... Oxidase reagent provides a long shelf ...
Medicine Products: